Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2010

Open Access 01-05-2010

Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy

Authors: W.-Ludo van der Pol, Elisabeth A. Cats, Leonard H. van den Berg

Published in: Journal of Clinical Immunology | Special Issue 1/2010

Login to get access

Abstract

Introduction

Multifocal motor neuropathy (MMN) is characterized by asymmetric weakness of limbs and the electrophysiological finding of conduction block in motor nerves. Conduction block is the inability of nerves to propagate action potentials and is probably caused by immune-mediated dysfunction of the axon at the nodes of Ranvier or the myelin sheath. MMN immune pathogenesis has not been elucidated.

Results

In approximately 50% of all patients, IgM antibodies that bind to the glycolipid GM1, which is abundantly expressed in peripheral motor nerves, can be detected. A recent study showed an association with HLA-DRB1*15, and virtually all patients respond to treatment with intravenous immunoglobulin (IVIG) in at least the early stages of the disease.

Conclusion

This review aims at providing a concise overview of what is known about MMN pathogenesis, and how the beneficial effect of IVIG might be explained.
Literature
1.
go back to reference Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.CrossRefPubMed Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73–8.CrossRefPubMed
3.
go back to reference Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–19.CrossRefPubMed Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–19.CrossRefPubMed
4.
go back to reference Corbo M, Abouzahr MK, Latov N, Iannaccone S, Quattrini A, Nemni R, et al. Motor nerve biopsy studies in motor neuropathy and motor neuron disease. Muscle Nerve. 1997;20:15–21.CrossRefPubMed Corbo M, Abouzahr MK, Latov N, Iannaccone S, Quattrini A, Nemni R, et al. Motor nerve biopsy studies in motor neuropathy and motor neuron disease. Muscle Nerve. 1997;20:15–21.CrossRefPubMed
5.
go back to reference Taylor BV, Dyck PJ, Engelstad J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol. 2004;63:129–37.PubMed Taylor BV, Dyck PJ, Engelstad J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol. 2004;63:129–37.PubMed
6.
go back to reference Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain. 2002;125:664–75.CrossRefPubMed Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain. 2002;125:664–75.CrossRefPubMed
7.
go back to reference Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:743–7.CrossRefPubMed Van Asseldonk JT, Van den Berg LH, Kalmijn S, Van den Berg-Vos RM, Polman CH, Wokke JH, et al. Axon loss is an important determinant of weakness in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:743–7.CrossRefPubMed
8.
go back to reference Priori A, Bossi B, Ardolino G, Bertolasi L, Carpo M, Nobile-Orazio E, et al. Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy. Brain. 2005;128:1642–8.CrossRefPubMed Priori A, Bossi B, Ardolino G, Bertolasi L, Carpo M, Nobile-Orazio E, et al. Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy. Brain. 2005;128:1642–8.CrossRefPubMed
9.
go back to reference Priori A, Cinnante C, Pesenti A, Carpo M, Cappellari A, Nobile-Orazio E, et al. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain. 2002;125:2481–90.CrossRefPubMed Priori A, Cinnante C, Pesenti A, Carpo M, Cappellari A, Nobile-Orazio E, et al. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain. 2002;125:2481–90.CrossRefPubMed
10.
go back to reference Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007;27:3956–67.CrossRefPubMed Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci. 2007;27:3956–67.CrossRefPubMed
11.
go back to reference Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591–625.CrossRefPubMed Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591–625.CrossRefPubMed
12.
go back to reference Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197–208.CrossRefPubMed Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131:1197–208.CrossRefPubMed
13.
go back to reference Uetz-von Allmen E, Sturzenegger M, Rieben R, Rihs F, Frauenfelder A, Nydegger UE. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. Eur Neurol. 1998;39:103–10.CrossRefPubMed Uetz-von Allmen E, Sturzenegger M, Rieben R, Rihs F, Frauenfelder A, Nydegger UE. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. Eur Neurol. 1998;39:103–10.CrossRefPubMed
14.
go back to reference Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205:101–4.CrossRefPubMed Phongsisay V, Susuki K, Matsuno K, Yamahashi T, Okamoto S, Funakoshi K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205:101–4.CrossRefPubMed
15.
go back to reference Terenghi F, Allaria S, Scarlato G, Nobile-Orazio E. Multifocal motor neuropathy and Campylobacter jejuni reactivity. Neurology. 2002;59:282–4.PubMed Terenghi F, Allaria S, Scarlato G, Nobile-Orazio E. Multifocal motor neuropathy and Campylobacter jejuni reactivity. Neurology. 2002;59:282–4.PubMed
16.
go back to reference Sutedja NA, Otten HG, Cats EA, Piepers S, Veldink JH, van der Pol WL, et al. Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy. Neurology. 2010;74:828–32.CrossRefPubMed Sutedja NA, Otten HG, Cats EA, Piepers S, Veldink JH, van der Pol WL, et al. Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy. Neurology. 2010;74:828–32.CrossRefPubMed
17.
go back to reference De Angelis MV, Notturno F, Caporale CM, Pace M, Uncini A. Polymorphisms of CD1 genes in chronic dysimmune neuropathies. J Neuroimmunol. 2007;186:161–3.CrossRefPubMed De Angelis MV, Notturno F, Caporale CM, Pace M, Uncini A. Polymorphisms of CD1 genes in chronic dysimmune neuropathies. J Neuroimmunol. 2007;186:161–3.CrossRefPubMed
18.
go back to reference Terenghi F, Allaria S, Nobile-Orazio E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst. 2006;11:67–71.CrossRefPubMed Terenghi F, Allaria S, Nobile-Orazio E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst. 2006;11:67–71.CrossRefPubMed
19.
go back to reference Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59:S13–21.PubMed Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59:S13–21.PubMed
20.
go back to reference Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA. 2009;106:4788–92.CrossRefPubMed Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA. 2009;106:4788–92.CrossRefPubMed
Metadata
Title
Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy
Authors
W.-Ludo van der Pol
Elisabeth A. Cats
Leonard H. van den Berg
Publication date
01-05-2010
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue Special Issue 1/2010
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-010-9408-3

Other articles of this Special Issue 1/2010

Journal of Clinical Immunology 1/2010 Go to the issue